Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a vaccine teach the immune system to fight hepatitis b?

NCT ID NCT06070051

Disease control Sponsor: Virion Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental vaccine called VRON-0200 in adults with chronic hepatitis B who are already taking antiviral medication. The vaccine aims to boost the body's immune response against the virus. Some participants also receive two additional drugs, elebsiran and tobevibart, to see if combining them improves the effect. The study focuses on safety and whether the vaccine can stimulate a strong T-cell response.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VRON-0200, a therapeutic vaccine using two chimpanzee adenovirus vectors, sometimes combined with the drugs elebsiran (VIR-2218) and tobevibart (VIR-3434)
What this could lead to
If successful, this approach could help the immune system control chronic hepatitis B, potentially allowing some people to stop long-term antiviral medication.
What could go wrong
This is an early, small trial focused on safety and immune response, so it may not lead to a functional cure. The vaccine and drug combination could also cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

35 people

The number who actually took part.

Started

Sep 2023

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Documented chronic HBV infection (eg, HBsAg+ ≥ 6 months with detectable HBsAg at screening) 2. Receipt of either entecavir, tenofovir (tenofovir alafenamide fumarate or tenofovir disoproxil fumarate), or lamivudine for at least 12 months before screening with no reported antiviral resistance during this time; still on treatment at screening and expected to stay on therapy during the study period 3. Virally suppressed for \> 12 months (HBV DNA \< 40 IU/mL) 4. No clinical diagnosis of advanced liver fibrosis and/or cirrhosis Exclusion Criteria: 1. History of hepatic decompensation, advanced fibrosis, or liver transplantation 2. History of hepatocellular carcinoma 3. History of risk factors for thrombosis and thrombocytopenia 4. Documented hepatitis A, hepatitis C, hepatitis D, hepatitis E, or HIV (or history of prior active disease) 5. Pregnant, nursing, or planning a pregnancy during the trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic hepatitis B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic hepatitis B

Contacts and locations

Locations

  • Aotearoa Clinical Trials, Middlemore Hospital

    Auckland, New Zealand

  • Auckland City Hospital

    Auckland, New Zealand

  • Chinese University of Hong Kong

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.